http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016.

doi:
10.1176/appi.ajp.2015.173501. [PubMed 27133416]

205. Reznik I, Loewenthal R, Kotler M, Apter I, Mester R, Weizman A. Granulocytopenia associated with neuroleptic
therapy in a patient with benign familial leukopenia. Int J Psychiatry Clin Pract. 2003;7(4):277-280.
doi:10.1080/13651500310002977 [PubMed 24930415]

206. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60 suppl
10:5-14. [PubMed 10340682]

207. Risch SC. Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy. 1996;16(1 pt
2):11-14. [PubMed 8778681]

208. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022.
doi:10.1056/NEJMra032426 [PubMed 14999113]

209. Roessner V, Plessen KJ, Rothenberger A, et al; ESSTS Guidelines Group. European clinical guidelines for Tourette
syndrome and other tic disorders. Part II: pharmacological treatment [published correction appears in Eur Child
Adolesc Psychiatry. 2011;20(7):377]. Eur Child Adolesc Psychiatry. 2011;20(4):173-196. [PubMed 21445724]

210. Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of
chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer
patients. Ann Oncol. 2016;27(suppl 5):v119-v133. [PubMed 27664248]

211. Rosenheck R, Perlick D, Bingham S, et al; Department of Veterans Affairs Cooperative Study Group on the Cost-
Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of
schizophrenia: a randomized controlled trial. JAMA. 2003;290(20):2693-2702. doi: 10.1001/jama.290.20.2693.
[PubMed 14645311]

212. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or
haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Am J Psychiatry. 2002;159(7):1146-1154. doi: 10.1176/appi.ajp.159.7.1146. [PubMed 12091192]

213. Sadibašić B, Macić-Džanković A, Šabić A, Torlak B, Lastrić G, Ćustović A. The incidence of dyslipidemia
(hypertriglyceridemia and hypercholesterolemia) in patients treated with the new generation of antipsychotic
drugs compared to conventional therapy. Med Glas (Zenica). 2014;11(2):350-355. [PubMed 25082252]

214. Şahan E. Haloperidol-related neutropenia. Indian J Psychiatry. 2019;61(3):307-310.

215. Sassa T, Suhara T, Ikehira H, et al. 19F-magnetic resonance spectroscopy and chemical shift imaging for
schizophrenic patients using haloperidol decanoate. Psychiatry Clin Neurosci. 2002;56(6):637-642. [PubMed
12485307]

216. Scahill L, Erenberg G, Berlin CM Jr, et al; Tourette Syndrome Association Medical Advisory Board: Practice
Committee. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3(2):192-206.
[PubMed 16554257]

217. Scherer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M. D2-dopamine receptor occupancy differs
between patients with and without extrapyramidal side effects. Acta Psychiatr Scand. 1994;90(4):266-268.
doi:10.1111/j.1600-0447.1994.tb01591.x [PubMed 7831996]
218. Schieveld JN, Leentjens AF. Delirium in severely ill young children in the pediatric intensive care unit (PICU). J Am
Acad Child Adolesc Psychiatry. 2005;44(4):392-394. [PubMed 15782087]

219. Schieveld JN, Leroy PL, van Os J, Nicolai J, Vos GD, Leentjens AF. Pediatric delirium in critical illness:
phenomenology, clinical correlates and treatment response in 40 cases in the pediatric intensive care unit.
Intensive Care Med. 2007;33(6):1033-1040. [PubMed 17457571]

220. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of
conventional versus atypical antipsychotic drugs among elderly patients [published correction appears in CMAJ.
2007;176(11):1613]. CMAJ. 2007;176(5):627-632. doi:10.1503/cmaj.061250 [PubMed 17325327]

221. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-
analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943. doi:10.1001/jama.294.15.1934
[PubMed 16234500]

222. Schoretsanitis G, Westin AA, Deligiannidis KM, Spigset O, Paulzen M. Excretion of antipsychotics into the amniotic
fluid, umbilical cord blood, and breast milk: a systematic critical review and combined analysis. Ther Drug Monit.
2020;42(2):245-254. doi:10.1097/FTD.0000000000000692 [PubMed 31425493]

223. Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in
medical and surgical patients: case reports and a review of the literature. Psychosomatics. 2009;50(1):8-15.
doi:10.1176/appi.psy.50.1.8 [PubMed 19213967]

224. Serrano AC, “Haloperidol - Its Use in Children,” J Clin Psychiatry, 1981, 42(4):154-6. [PubMed 6937455]
225. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin
Psychopharmacol. 2011;26(3):130-140. doi:10.1097/YIC.0b013e328341e434 [PubMed 21191308]

226. Sethna R, Notkin R. Haloperidol-induced bronchospasm. Can J Psychiatry. 1991;36(7):525-526.

227. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J
Perinatol. 1989;9(2):170-172. [PubMed 2738729]

228. Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat
pediatric emergencies. Pediatrics. 2020;145(1):e20193450. [PubMed 31871244]

229. Slooff VD, Spaans E, van Puijenbroek E, et al. Adverse events of haloperidol for the treatment of delirium in
critically ill children. Intensive Care Med. 2014;40(10):1602-1603. [PubMed 25183567]

230. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159-169. [PubMed 17390261]
231. Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation
antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777.
doi:10.2147/TCRM.S117321 [PubMed 28721057]

232. Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci.
2018;389:21-27. doi:10.1016/j.jns.2018.02.012 [PubMed 29439776]

233. Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol.
2014;9(3):310-317. doi:10.2174/15748847113089990051 [PubMed 23343447]
234. Steinman M, Reeve E. Deprescribing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed December 17, 2020.

235. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and
neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. doi:10.1345/aph.1L066 [PubMed
18628446]

236. Stovall J. Bipolar mania and hypomania in adults: choosing pharmacology. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed March 10, 2021.

237. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death [published
correction appears in Arch Intern Med. 2004;164(17):1839]. Arch Intern Med. 2004;164(12):1293-1297.
doi:10.1001/archinte.164.12.1293 [PubMed 15226162]

238. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-876. [PubMed
17541044]

239. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry.
2018;17(3):341-356. doi:10.1002/wps.20567 [PubMed 30192094]

240. Stroup TS. Pharmacology of antipsychotics: Dosing (adult), formulations, kinetics and potential for drug
interactions. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 30,
2019a.

241. Stroup TS, Marder S. Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment. Post TW, ed.
UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 12, 2019b.

242. Suh KN, Keystone JS. Treatment of delusional infestation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed October 30, 2019.

243. Surveillance report 2016 – Psychosis and schizophrenia in children and young people: recognition and
management (2013) NICE guideline CG155. London: National Institute for Health and Care Excellence (UK);
November 3, 2016. [PubMed 31846256]

244. Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic
switching: a systematic review and meta-analysis. Schizophr Bull. 2017;43(4):862-871. doi:
10.1093/schbul/sbw171. [PubMed 28044008]

245. Tesar GE, Stern TA. Analytic reviews: rapid tranquilization of the agitated intensive care unit patient. J Intensive
Care Med. 1988;3(4):195-201. doi: 10.1177/088506668800300403

246. Teva-Haloperidol (haloperidol) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; August
2016.

247. Tietze KJ, Fuchs B. Sedative-analgesic medications in critically ill adults: Properties, dosage regimens, and adverse
effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 5, 2020.

248. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American
Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905 [PubMed 32929996]

249. Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval
prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual Outcomes.
 2013;6(6):e57]. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152
[PubMed 23716032]

250. Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of
QT interval prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual
Outcomes. 2014;7(6):981]. Circ Cardiovasc Qual Outcomes. 2014;7(3):381-390.
doi:10.1161/CIRCOUTCOMES.113.000651 [PubMed 24803473]

251. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord.
2000;2(3 Pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x [PubMed 11249804]

252. Tolppanen AM, Koponen M, Tanskanen A, et al. Antipsychotic use and risk of hospitalization or death due to
pneumonia in persons with and those without Alzheimer disease. Chest. 2016;150(6):1233-1241.
doi:10.1016/j.chest.2016.06.004 [PubMed 27298071]

253. Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and
second-generation antipsychotics. Br J Psychiatry. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189 [PubMed
22626633]

254. Turkel SB, Hanft A. The pharmacologic management of delirium in children and adolescents. Paediatr Drugs.
2014;16(4):267-274. [PubMed 24898718]

255. Uguz f. Adverse events in a breastfed infant exposed to risperidone and haloperidol. Breastfeed Med.
2019;14(9):683-684. doi:10.1089/bfm.2019.0093 [PubMed 31135176]

256. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with
schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic
review and meta-analysis. World Psychiatry. 2015;14(3):339-347. doi:10.1002/wps.20252 [PubMed 26407790]

257. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ. 1999;319(7210):623-626.
doi:10.1136/bmj.319.7210.623 [PubMed 10473482]

258. van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. Eur J Clin
Pharmacol. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4 [PubMed 17401555]

259. Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic
mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214-220.
doi:10.1097/JCP.0b013e31820e4832 [PubMed 21346608]

260. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet
Mov (N Y). 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71 [PubMed 23858394]

261. Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 updated MASCC/ESMO consensus
recommendations: Management of nausea and vomiting in advanced cancer. Support Care Cancer.
2017;25(1):333-340. [PubMed 27534961]

262. Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a
criterion for reconsidering treatment? Results from an individual patient data meta-analysis. J Clin Psychiatry.
2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051 [PubMed 27780320]

263. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.
Dtsch Arztebl Int. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687 [PubMed 22114630]
264. Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Treatment with antipsychotics in pregnancy:
changes in drug disposition. Clin Pharmacol Ther. 2018;103(3):477-484. doi:10.1002/cpt.770 [PubMed 28643331]

265. Whalley LJ, Blain PG, and Prime JK, “Haloperidol Secreted in Breast Milk,” Br Med J (Clin Res Ed), 1981,
282(6278):1746-7. [PubMed 6786603]

266. Willner MM, Gordon LE. Psychotropic drugs in children. Pharmacotherapy as an adjunct to counseling or
psychotherapy. Clin Pediatr (Phila). 1969;8(4):193-200. [PubMed 4887476]

267. Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in
combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med.
2012b;43(5):790-797. [PubMed 21601409]

268. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus
statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup.
West J Emerg Med. 2012a;13(1):26-34. doi: 10.5811/westjem.2011.9.6866. [PubMed 22461918]

269. Wu CS, Wang SC, Yeh IJ, Liu SK. Comparative risk of seizure with use of first- and second-generation antipsychotics
in patients with schizophrenia and mood disorders. J Clin Psychiatry. 2016;77(5):e573-e579.
doi:10.4088/JCP.15m09898 [PubMed 27249081]

270. Yasuhara Y, Hirai E, Sakamaki S, et al. Using ultrasonography in the intramuscular injection techniques used for
administering drug treatments to schizophrenic patients in Japan. J Med Invest. 2012;59(1-2):213-219. [PubMed
22450010]

271. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and
International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar
disorder. Bipolar Disord. 2018;20(2):97-170. doi: 10.1111/bdi.12609. [PubMed 29536616]

272. Yoshida K, Smith B, and Kumar R, “Psychotropic Drugs in Mothers' Milk: A Comprehensive Review of Assay
Methods, Pharmacokinetics and of Safety of Breast-Feeding,” J Psychopharmacol, 1999, 13(1):64-80. [PubMed
10221361]

273. Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: a
systematic review. Front Psychiatry. 2017;8:165. doi:10.3389/fpsyt.2017.00165 [PubMed 28936184]

274. Zou D, Shao Y, Qin Z, et al. Death due to fulminant neuroleptic malignant syndrome induced by low doses of
haloperidol: a rare case. J Forensic Leg Med. 2014;24:12-14. doi:10.1016/j.jflm.2014.02.011 [PubMed 24794843]

Topic 8516 Version 476.0